Skip to content
Clinical ResearchResearch compound

MOTS‑c

Research peptide that affects sugar and fat metabolism; it worked in mice, but in humans only early studies exist.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

MOTS-c vial

DETAILED OVERVIEW

What is MOTS-c?

MOTS-c is a peptide, a short protein chain of 16 amino acids, that the body itself makes in the mitochondria (the energy-producing parts of cells). It has not been approved as a medicine anywhere, and it has also appeared on the black market as a research peptide. It switches on an enzyme called AMPK (the cell's energy sensor), in a way similar to metformin, a diabetes medicine: in skeletal muscle it increases sugar uptake and the burning of fatty acids.

Given to mice, it prevented obesity and insulin resistance caused by a high-fat diet. In humans there are so far only early studies; the full safety profile and long-term effects are not known, and the fat-loss effect is small. It can cause low blood sugar, especially during a calorie deficit or together with insulin or other diabetes medicines. It should be avoided in pregnancy, because there are no safety data. In competitive sport it may count as banned under the general ban on unapproved substances.

Mechanism

Mitochondrial peptide; switches on the cell's energy sensor (AMPK)

Half-life

~1-2 hours (SC IM, mouse extrapolation)

Onset time

Enzyme activation within 1-2 hours; metabolic effect in 2-4 weeks

Legal status

Research-only – NOT an FDA / EMA Rx in any jurisdiction. WADA NOT explicitly banned (but S0 'non-approved substance' catch-all risk).

Data console

Lab data

Androgenic:AnabolicN/A (not an AAS, mitochondrial-derived peptide)
AR bindingReceptor target is not well characterized – AMPK…
Active half-life~1-2 hours (SC, mouse extrapolation)
Detection windowWADA-accredited LC-MS/MS detectable in human plasma ~24-48 h after a single dose (Reynolds 2021 PMID 33526809 endogenous MOTS-c assay baseline ~50-200 pg/mL). Exogenous supraphysiological doses are distinguishable from endogenous baseline by mass-spec isotope pattern.
AromatizationDoes not aromatize – mitochondrial peptide, not steroid-related. No CYP19 interaction; the estrogen axis is directly unaffected.
HepatotoxicityLow – endogenous mitochondrial peptide; supraphysiological-dose evidence is preclinical-only in humans. ALT/AST elevation has not been documented in preliminary clinical trials, but full Phase 2 publication is expected in 2026.

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Risk of hypoglycemia: as an AMPK activator it improves insulin sensitivity and drives insulin-independent glucose uptake, so blood sugar can drop, especially in a calorie deficit or combined with other antidiabetics (metformin, insulin, GLP-1).
  • Local injection-site reactions: redness, tenderness, itching or swelling at the subcutaneous injection site.
  • Gastrointestinal complaints: its AMPK-activating mechanism parallels metformin, so nausea, bloating or mild digestive discomfort may occur (anecdotal, human dosing data sparse).
  • Lactate elevation and theoretical metabolic acidosis risk: as a modulator of mitochondrial metabolism it may raise lactate; a marked rise (>2x baseline) warrants dose reduction or stopping the cycle.
  • Unknown long-term safety profile: human data are at a preliminary Phase 1/2 stage and the full safety profile is unpublished as of early 2026; effects of supraphysiological, long-term dosing are unknown.
  • Black-market quality risk: illicit UGL vials carry the risk of counterfeiting, underdosing, degraded peptide and endotoxin contamination; without an HPLC-tested source and COA the actual content and purity are uncertain.

Contraindications · 6

  • Pregnancy and breastfeeding: the peptide has only preclinical data with no teratogenicity information, so it should be avoided during pregnancy and lactation.
  • Diabetes treated with insulin or a sulfonylurea: the insulin-sensitizing effect is additive with a risk of severe hypoglycemia; contraindicated without close glucose monitoring and medical supervision.
  • Active malignancy: the preclinical proliferation data of this mitochondrial-biogenesis modulator are inconclusive, so it should be avoided in active cancer (theoretical risk).
  • Children and adolescents: there is no Phase 2 indication or safety data for pediatric use, so it is contraindicated.
  • Conditions predisposing to lactic acidosis (renal or hepatic impairment, chronic alcohol use): the AMPK-activator mechanism and lactate-raising potential may add hepatic/metabolic stress, warranting heightened caution or avoidance.
  • Known hypersensitivity to the peptide or to components of the reconstitution solution: local or, rarely, systemic allergic reactions may occur.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about MOTS‑c?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.